Boston Therapeutics, Inc. announced that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes portfolio. Formerly of Eli Lilly and Merck and company, Upham brings both large pharmaceutical experience and private development stage company experience to the Boston Therapeutics team. Upham will report directly to CEO, Carl Rausch, and work closely with investment bank operations and US based partners to support operations in the US.